Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune ...

Reported net loss of $6.8 million and adjusted net loss of $5.2 million, attributed to a "softer earnings environment" and ...

With the seasonally weak first quarter now behind Seanergy Maritime, profitability and cash generation should improve ...

Despite a net loss, Seanergy Maritime Holdings Corp (SHIP) focuses on strategic fleet expansion and financial flexibility to ...

A clear regulatory pathway in this orphan disease in US could make YK012 one of the first approved TCE in the autoimmune space with many other autoimmune and oncology indications to follow.

The IRS issued an important warning in April of 2025, alerting Americans to the fact that around $1 billion in refunds remain ...

Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune ...

(3) Daily Time Charter Equivalent Rate (“TCE”) and TCE Revenues are non-GAAP ... The Board declared a $0.05 per share dividend, marking our 17th consecutive quarter of capital returns ...

Q1 2025 Earnings Call Transcript May 27, 2025 Seanergy Maritime Holdings Corp. beats earnings expectations. Reported EPS is $ ...

May 21, 2025Golden Ocean Group Limited misses on earnings expectations. Reported EPS is $-0.19231 EPS, expectations were $-0.1. Operator: Good day, and thank you for standing by. Welcome to the First ...

To derive Adjusted EBITDA from EBITDA, we exclude certain non-cash gains / (losses). (3) Daily Time Charter Equivalent Rate ("TCE”) and TCE Revenues are non-GAAP measures. Please see EXHIBIT I at the ...

KBRA assigns a senior unsecured debt rating of BBB, a subordinated debt rating of BBB-, and a short-term debt rating of K3 to Elmira, NY-based Chemung Financial Corporation (NASDAQ: CHMG) ("the ...